PI3K/AKT/mTOR Activation Is Associated With Malignant Severity and Poorer Prognosis in Parathyroid Carcinomas
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgaf042 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Jia-Xi Song und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong Universit…. Hauptthemen laut MEDLINE: TOR Serine-Threonine Kinases, Proto-Oncogene Proteins c-akt, Parathyroid Neoplasms, Phosphatidylinositol 3-Kinases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Sailing Program, Programs for Science and Technology Development of Henan province.
Abstract (Originalsprache)
Context and Objective Parathyroid carcinoma (PCa) is a rare endocrine neoplasm known for its high recurrence. The specific molecular properties influencing the prognosis of PCa remain largely elusive. The present study was designed to explore the significance of PI3K/AKT/mTOR activation in PCa.
Methods
Over a 10-year period, 64 PCa patients were recruited from dual centers. We analyzed mechanistic target of rapamycin complex I (mTORC1) activity in 64 PCa patients and 29 controls, comprising atypical parathyroid tumor (APT), parathyroid adenoma (PAd), and normal parathyroid tissues. A panel of selected genes targeting the PI3K/AKT/mTOR pathway (PIK3CA, PTEN, MTOR, TSC1, and TSC2) and CDC73 was performed in 66 available tumor tissues from 64 patients with PCa. Follow-up lasted up to 117 months.
Results
There was intertumoral heterogeneity in mTORC1 activity in parathyroid tumors. Notably, we observed significantly elevated mTORC1 activity in PCa patients compared with controls, as assessed by immunohistochemical staining of tissue sections. Further analysis showed that 48.5% of PCa tumors were classified as “high mTORC1” (above the predefined threshold), while only 22.7% of tumors in the PAd/APT group met this criterion. Additionally, we detected PI3K/AKT/mTOR variants in 16/66 (24.2%) PCa samples, with the majority lacking CDC73 variants. Higher mTORC1 activity was noted in PCa with PI3K/AKT/mTOR variants than in those without. Compared with those without any targeted variants, the PI3K/AKT/mTOR-mutated group presented higher levels of serum PTH, alkaline phosphatase, and creatinine and was associated with significantly lower disease-free survival (DFS) and overall survival (OS) (DFS, P < .001; OS, P < .01).
Conclusion
Our findings highlight that the activation of the PI3K/AKT/mTOR pathyway in PCa patients suggests their degree of malignancy, possibly leading to poor outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
- Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, Stat…
- Department of Thyroid Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
- Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
- Department of Thyroid and Vascular Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
ORCID-Profile: Guang Ning, Lei Ye, Xiu-Bo Lu, Jian-Min Liu
Förderung
- National Natural Science Foundation of China
- Shanghai Sailing Program
- Programs for Science and Technology Development of Henan province
- Central Research Institute Fund of Chinese Academy of Medical Sciences
Zitieren
APA
Song, J. X., Dong, Y. Q., Han, R. L., Xie, J., Zhu, A. Y., Chen, X., Yang, Y. Y., Sheng, C. X., Jiang, T., Zhao, H. Y., Tao, B., Ning, G., Wang, W. Q., Sun, L. H., Ye, L., Lu, X. B., & Liu, J. M. (2025). PI3K/AKT/mTOR Activation Is Associated With Malignant Severity and Poorer Prognosis in Parathyroid Carcinomas. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf042
Vancouver
Song JX, Dong YQ, Han RL, Xie J, Zhu AY, Chen X, et al. PI3K/AKT/mTOR Activation Is Associated With Malignant Severity and Poorer Prognosis in Parathyroid Carcinomas. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf042
BibTeX
@article{Song2025,
author = {Song, Jia-Xi and Dong, Yong-Qiang and Han, Ru-Lai and Xie, Jing and Zhu, An-Ying and Chen, Xi and Yang, Yu-Ying and Sheng, Chun-Xiang and Jiang, Tao and Zhao, Hong-Yan and Tao, Bei and Ning, Guang and Wang, Wei-Qing and Sun, Li-Hao and Ye, Lei and Lu, Xiu-Bo and Liu, Jian-Min},
title = {PI3K/AKT/mTOR Activation Is Associated With Malignant Severity and Poorer Prognosis in Parathyroid Carcinomas},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgaf042}
}
EUVIMED